Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
Yahoo! Finance
PALO ALTO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company today announced that researchers at Oxford Population Health’s Health Economics Research Centre and the Kennedy Institute of Rheumatology have found that anti-TNF treatment (adalimumab), which is commonly used to treat conditions such as rheumatoid arthritis and psoriasis, is likely to be a cost-effective treatment for people a
Continue Reading